Jessica Chubak, PhD
Research interests and experience
- Cancer control: epidemiology; breast cancer; medication use; survivorship; secondary prevention; quality of life; automated data collection; screening
- Health services & economics: chronic illness management; translation of preventive care research into clinical practice
- Medication use & patient safety: pharmaceutical outcomes research; validation of pharmacy data resources
Jessica Chubak joined Group Health Research Institute (GHRI) in 2007 with a passion for epidemiology and improving health care. With expertise in epidemiologic methods, pharmaco-epidemiology, and cancer, she is working with the Institute's cancer researchers to explore new inquiries in cancer screening and survivorship.
Dr. Chubak serves as the GHRI site principal investigator for the HMO Cancer Research Network. She also participates in several projects on medication use and cancer risk and prognosis. She is especially interested in evaluating programs and translating research into practices that improve health and health care.
Awarded a Fulbright graduate student grant, Dr. Chubak pursued her master's degree in bioethics and health law in New Zealand. This unique background has helped shape her commitment to moving research innovations into daily practice, especially for cancer survivors. She is building a research program in cancer screening and survivorship focused on preventing cancer death, recurrence, and late and long-term adverse effects of cancer treatment. She aims to develop epidemiologic methods for large-scale research on cancer screening and care management for cancer survivors.
Dr. Chubak is an affiliate assistant professor in the Department of Epidemiology at the University of Washington School of Public Health and serves as co-chair of GHRI’s Scientific Policy Committee. A member of the American Society of Preventive Oncology and the Society for Epidemiologic Research, she also serves as a peer reviewer for a dozen journals, including Medical Care, the Journal of Oncology Practice, and the Journal of Clinical Epidemiology.
Laing SS, Bogart A, Chubak J, Fuller S, Green BB. Psychological distress after a positive fecal occult blood test result among members of an integrated healthcare delivery system. Cancer Epidemiol Biomarkers Prev. 2013 Nov 12. [Epub ahead of print].
Hamilton JG, Birmingham WS, Tehranifar P, Irwin ML, Klein WM, Nebling L, Chubak J. Transitioning to independence and maintaining a career in the new funding climate: a report from the American Society of Preventive Oncology’s Junior Members Interest Group. Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2138-42. doi: 10.1158/1055-9965.EPI-13-0807.
Chubak J, Bogart A, Fuller S, Laing SS, Green BB. Uptake and positive predictive value of fecal occult blood tests: a randomized controlled trial. Prev Med. 2013 Sep 9. pii: S0091-7435(13)00324-1. doi: 10.1016/j.ypmed.2013.08.032. [Epub ahead of print].
Chubak J, Boudreau DM, Wirtz HS, McKnight B, Weiss NS. Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J Natl Cancer Inst. 2013 Aug 12 [Epub ahead of print]. PubMed
Wirtz HS, Buist DS, Gralow JR, Barlow WE, Gray SL, Chubak J, Yu O, Bowles EJ, Fujii M, Boudreau DM. Frequent antibiotic use and second breast cancer events. Cancer Epidemiol Biomarkers Prev. 2013 Jul 5 [Epub ahead of print].
Chubak J, Yu O, Buist DS, Wirtz HS, Boudreau DM. Time scale in follow-up studies: considering disease prognosis. Epidemiology. 2013;24(4):628-9. doi: 10.1097/EDE.0b013e3182961708. PubMed
Lowry SJ, Chubak J, Press OW, McKnight B, Weiss NS. Risk of non-Hodgkin lymphoma in relation to tricyclic antidepressant use. Ann Epidemiol. 2013;23(6):349-54. doi: 10.1016/j.annepidem.2013.04.006. PubMed
Chubak J, Rutter CM, Kamineni A, Johnson EA, Stout NK, Weiss NS, Doria-Rose VP, Doubeni CA, Buist DS. Measurement in comparative effectiveness research. Am J Prev Med. 2013 May;44(5):513-9. doi: 10.1016/j.amepre.2013.01.006. PubMed
Green BB, Wang CY, Anderson ML, Chubak J, Meenan RT, Vernon SW, Fuller S. An automated intervention with stepped increases in support to increase uptake of colorectal cancer screening: a randomized trial. Ann Intern Med. 2013;158(5 Pt 1):301-11. doi: 10.7326/0003-4819-158-5-201303050-00002. PubMed
Doubeni CA, Weinmann S, Adams K, Kamineni A, Buist DS, Ash AS, Rutter CM, Doria-Rose VP, Corley DA, Greenlee RT, Chubak J, Williams A, Kroll-Desrosiers AR, Johnson E, Webster J, Richert-Boe K, Levin TR, Fletcher RH, Weiss NS. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med. 2013;158(5 Pt 1):312-20. doi: 10.7326/0003-4819-158-5-201303050-00003. PubMed
To view more publications, please see Dr. Chubak's CV.